Mitochondrial-dependent apoptosis in Huntington's disease human cybrids

Experimental Neurology

Volumn 222, Issue 2, 2010, Pages 243-255

  Ferreira, Ildete L ^a   Nascimento, Maria V ^a   Ribeiro, Márcio ^a   Almeida, Sandra ^a   Cardoso, Sandra M ^a   Grazina, Manuela ^a,b   Pratas, João ^a   Santos, Maria João ^a   Januário, Cristina ^c   Oliveira, Catarina R ^a,b   Rego, A Cristina ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

3 Nitropropionic acid; Apoptosis; Human cybrids; Huntington's disease; Mitochondria

Indexed keywords

3 NITROPROPIONIC ACID; APOPTOSIS INDUCING FACTOR; BIM PROTEIN; CASPASE 3; CYTOCHROME C; CYTOCHROME C OXIDASE; HYDROPEROXIDE; MITOCHONDRIAL DNA; PROTEIN BAX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STAUROSPORINE; SUPEROXIDE;

APOPTOSIS; ARTICLE; CELL FUSION; CELL NUCLEUS; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYBRID; DNA SEQUENCE; ENZYME ACTIVATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NEUROPATHOLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TRANSPORT; RESPIRATORY CHAIN; THROMBOCYTE;

ADULT; ANALYSIS OF VARIANCE; APOPTOSIS; APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CASE-CONTROL STUDIES; CASPASE 3; CELL LINE, TUMOR; CITRATE (SI)-SYNTHASE; DNA, MITOCHONDRIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX III; ELECTRON TRANSPORT COMPLEX IV; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; INTRACELLULAR FLUID; L-LACTATE DEHYDROGENASE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MITOCHONDRIA; MULTIENZYME COMPLEXES; NITROBENZOATES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; STAUROSPORINE; SUBCELLULAR FRACTIONS; SUPEROXIDES; TERATOCARCINOMA; TIME FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 77549084450     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.01.002     Document Type: Article

References (53)

1. Acevedo-Torres K., Berríos L., Rosario N., Dufault V., Skatchkov S., Eaton M.J., Torres-Ramos C.A., and Ayala-Torres S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair 8 (2009) 126-136
2. Almeida S., Domingues A., Rodrigues L., Oliveira C.R., and Rego A.C. FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol. Dis. 17 (2004) 435-444
3. Almeida S., Brett A.C., Góis I.N., Oliveira C.R., and Rego A.C. Caspase-dependent and -independent cell death induced by 3-nitropropionic acid in rat cortical neurons. J. Cell Biochem. 98 (2006) 93-101
4. Almeida S., Sarmento-Ribeiro A.B., Januário C., Rego A.C., and Oliveira C.R. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. Biochem. Biophys. Res. Commun. 374 (2008) 599-603
5. Almeida S., Laço M., Cunha-Oliveira T., Oliveira C.R., and Rego A.C. BDNF regulates BIM expression levels in 3-nitropropionic acid-treated cortical neurons. Neurobiol. Dis. 35 (2009) 448-456
6. Aronin N., Chase K., Young C., Sapp E., Schwarz C., Matta N., Kornreich R., Landwehrmeyer B., Bird E., Beal M.F., Vonsattel J.P., Smith T., Carraway R., Boyce F.M., Young A.B., Penney J.B., and DiFiglia M. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron 15 (1995) 1193-1201
7. Banoei M.M., Houshmand M., Panahi M.S.S., Shariati P., and Rostami M. Huntington's disease and mitochondrial DNA deletions: Event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?!. Cell Mol. Neurobiol. 27 (2007) 867-875
8. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
9. Behrens M.I., Koh J., Canzoniero L.M., Sensi S.L., Csernansky C.A., and Choi D.W. 3-Nitropropionic acid induces apoptosis in cultured striatal and cortical neurons. Neuroreport 6 (1995) 545-548
10. Bergmeyer H.U., and Bernt E. UV-assay with pyruvate and NADH. Methods of enzymatic analysis (1974), Academic press, New York 574-579
11. Bezprozvanny I., and Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophy. Res. Comm. 322 (2004) 1310-1317
12. Bossy-Wetzel E., Petrilli A., and Knott A.B. Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci. 31 (2008) 609-616
13. Brouillet E., Guyot M.C., Mittoux V., Altairac S., Condé F., Palfi S., and Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70 (1998) 794-804
14. Brouillet E., Jacquard C., Bizat N., and Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95 (2005) 1521-1540
15. Cardoso S.M., Santana I., Swerdlow R.H., and Oliveira C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem. 89 (2004) 1417-1426
16. Carré M., André N., Carles G., Borghi H., Brichese L., Briand C., and Braguer D. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J. Biol. Chem. 277 (2002) 33664-33679
17. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., and Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13 (2004) 1407-1420
18. Ciammola A., Sassone J., Alberti L., Meola G., Mancinelli E., Russo M.A., Squitieri F., and Silani V. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ. 13 (2006) 2068-2078
19. del Hoyo P., García-Redondo A., de Bustos F., Molina J.A., Sayed Y., Alonso-Navarro H., Caballero L., Arenas J., and Jiménez-Jiménez F.J. Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease. Neurochem. Res. 31 (2006) 1103-1109
20. Esteves A.R., Domingues A.F., Ferreira I.L., Januário C., Swerdlow R.H., Oliveira C.R., and Cardoso S.M. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 8 (2008) 219-228
21. Fan M.M.Y., and Raymond L.A. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 81 (2007) 272-293
22. García-Martínez J.M., Pérez-Navarro E., Xifró X., Canals J.M., Díaz-Hernández M., Trioulier Y., Brouillet E., Lucas J.J., and Alberch J. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. J. Neurosci. Res. 85 (2007) 2756-2769
23. Gil J.M., and Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27 (2008) 2803-2820
24. Grazina M., Pratas J., Silva F., Oliveira S., Santana I., and Oliveira C. Genetic basis of Alzheimer's dementia: role of mtDNA mutations. Genes Brain Behav. 5 S2 (2006) 92-107
25. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 11 (1996) 136-142
26. Kasraie S., Houshmand M., Banoei M.M., Ahari S.E., Panahi M.S., Shariati P., Bahar M., and Moin M. Investigation of tRNA(Leu/Lys) and ATPase 6 Genes Mutations in Huntington's Disease. Cell. Mol. Neurobiol. 28 (2008) 933-938
27. Kuhn A., Goldstein D.R., Hodges A., Strand A.D., Sengstag T., Kooperberg C., Becanovic K., Pouladi M.A., Sathasivam K., Cha J.H., Hannan A.J., Hayden M.R., Leavitt B.R., Dunnett S.B., Ferrante R.J., Albin R., Shelbourne P., Delorenzi M., Augood S.J., Faull R.L., Olson J.M., Bates G.P., Jones L., and Luthi-Carter R. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16 (2007) 1845-1861
28. Kroemer G., and Reed J.C. Mitochondrial control of cell death. Nat. Med. 6 (2000) 513-519
29. Liu C.S., Cheng W.L., Kuo S.J., Li J.Y., Soong B.W., and Wei Y.H. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J. Neurol. Sci. 264 (2008) 18-21
30. Mancuso M., Orsucci D., Siciliano G., and Murri L. Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first?. Curr. Alzheimer Res. 5 (2008) 457-468
31. Milakovic T., and Johnson G.V.W. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem. 35 (2005) 30773-30782
32. Morimoto N., Nagano I., Deguchi K., Murakami T., Fushimi S., Shoji M., and Abe K. Leber hereditary optic neuropathy with chorea and dementia resembling Huntington disease. Neurology 63 (2004) 2451-2552
33. Oliveira J.M., Chen S., Almeida S., Riley R., Goncalves J., Oliveira C.R., Hayden M.R., Nicholls D.G., Ellerby L.M., and Rego A.C. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci. 26 (2006) 11174-11186
34. Onyango I., Khan S., Miller B., Swerdlow R., Trimmer P., and Bennett Jr. P. Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease. J. Alzheimers Dis. 9 (2006) 183-193
35. Pang Z., and Geddes J.W. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J. Neurosci. 17 (1997) 3064-3073
36. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., and Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5 (2002) 731-736
37. Perluigi M., Poon H.F., Maragos W., Pierce W.M., Klein J.B., Calabrese V., Cini C., De Marco C., and Butterfield D.A. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol. Cell Proteomics 4 (2005) 1849-1861
38. Rego A.C., and de Almeida L.P. Molecular targets and therapeutic strategies in Huntington's disease. Curr. Drug Targets 4 (2005) 361-381
39. Ruan Q., Lesort M., MacDonald M.E., and Johnson G.V. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum. Mol. Genet. 13 (2004) 669-681
40. Sas K., Robotka H., Toldi J., and Vécsei L. Mitochondria, metabolic disturbances, oxidative stress and kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 257 (2007) 221-239
41. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler J.F.J., Greenamyre J.T., Snyder S.H., and Ross C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 10 (1999) 1194-1198
42. Schapira A.H. Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta 1366 (1998) 225-233
43. Sorolla M.A., Reverter-Branchat G., Tamarit J., Ferrer I., Ros J., and Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic. Biol. Med. 45 (2008) 667-678
44. Swerdlow R.H., Parks J.K., Cassarino D.S., Shilling A.T., Bennett Jr. J.P., Harrison M.B., and Parker Jr. W.D. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochem. Biophys. Res. Commun. 291 (1999) 701-704
45. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., and Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45 (1999) 25-32
46. Treco D.A. Preparation of genomic DNA. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seideman J.G., Smith J.A., and Struh K. (Eds). Current protocols in molecular biology 21 (1999), Greene Publishing Associates and Wiley-Interscience, New York 2-17
47. Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y., Weber C., Agid Y., Hirsch E.C., and Mandel J.L. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet. 10 (1995) 104-110
48. Turner C., Cooper J.M., and Schapira A.H. Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov. Disord. 22 (2007) 1715-1721
49. Vanlangenakker N., Berghe T.V., Krysko D.V., Festjens N., and Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr. Mol. Med. 8 (2008) 207-220
50. Ward M.W., Rego A.C., Frenguelli B.G., and Nicholls D.G. Mitochondrial membrane potential and glutamate excitotoxicity in cultured cerebellar granule cells. J. Neurosci. 20 (2000) 7208-7219
51. Weber A., Paschen S.A., Heger K., Wilfling F., Frankenberg T., Bauerschmitt H., Seiffert B.M., Kirschnek S., Wagner H., and Häcker G. BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J. Cell Biol. 177 (2007) 625-636
52. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., Ierino H., Lee E.F., Fairlie W.D., Bouillet P., Strasser A., Kluck R.M., Adams J.M., and Huang D.C. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 (2007) 856-859
53. Yang J.-L., Weissman L., Bohr V., and Mattson M.P. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair 7 (2008) 1110-1120